Deep TMS (H-coil) by BrainsWay: status and timeline

Milestones

Next · 1,950 systems installed base

FDA clears Deep TMS for major depression2013Complete.
FDA clears for OCD2018Complete.
FDA clears for smoking cessation2020Complete.
Accelerated SWIFT protocol approved2025Complete.
1,000 systems deployed milestone2024Complete.
1,950 systems installed baseTarget Q2 2026Current milestone.

Most important, last 3 months

BrainsWay raises 2026 revenue guidance to $68–70M (+30–34%) on Q2 earningsAug 2026

Upcoming

2026Broadening reimbursement for accelerated SWIFT (next)
Q2 20261,950 systems installed base

Current obstacles

Variable treatment responseResponse rates vary across patients; some show full remission while others show minimal improvement.
Treatment durationEven accelerated protocols require weeks of outpatient sessions, which burdens compliance.

Physics limits

Skull absorption and blurringMagnetic fields pass through the skull without surgery, but the skull blurs and disperses the field, limiting precision and reach.
Single-focus limitationA stationary coil stimulates one brain region; treating multiple targets sequentially requires moving the coil or multiple sessions.

How it works

3 parts

H-coil design

Deeper penetration than flat coils

The H-shaped magnetic coil reaches the dorsolateral prefrontal cortex and other deep structures involved in mood and compulsive behaviour.

Repetitive stimulation

Weekly sessions over weeks

Patients receive sessions 5 days a week for 4–6 weeks (standard) or 4 weeks (accelerated SWIFT). Each session applies thousands of high-frequency pulses.

Outpatient procedure

No surgery or anesthesia

The coil sits on the scalp. Patients are awake and can return home after each session.

Spec sheet

Spec	Deep TMS (H-coil)
Systems in installed base	1,950^R (reported)
Standard protocol duration	6 weeks^R (reported)
Accelerated SWIFT duration	4 weeks^R (reported)
Session duration	20–30 minutes^R (reported)
US covered lives with reimbursement	57 million^R (reported)

^R reported by the company

Update log

1 update

Aug 2026

Major: BrainsWay raises 2026 revenue guidance to $68–70M (+30–34%) on Q2 earningsPressCommercial

About BrainsWay

The team behind Deep TMS (H-coil)

BrainsWay

Deep TMS H-coil, depression OCD

BrainsWay develops Deep TMS systems using H-coil technology for non-invasive treatment of depression, OCD and smoking addiction. Publicly traded on NASDAQ and TASE.

2026 revenue guidance raised to $68–70M (+30–34%); SWIFT protocol reaches 57M covered lives.
Q2 2026: revenue +35% to $17.1M, 125 systems shipped, 12th consecutive profitable quarter.
FDA-cleared for depression, OCD, smoking; 1,950 systems installed; trading NASDAQ BWAY and TASE BRIN.

brainsway.com (opens brainsway.com)Company profile →

Founded: 200323 yrs
Headquarters: Israel
Status: Public
Valuation: public
Works in: NeurotechStimulation therapies
Coverage: 1 program · 1 updatelatest 1 Aug 2026checked 11 Oct
People: Hadar LevyChief Executive Officer

Spec

Deep TMS (H-coil)

Systems in installed base

1,950^R (reported)

Standard protocol duration

6 weeks^R (reported)

Accelerated SWIFT duration

4 weeks^R (reported)

Session duration

20–30 minutes^R (reported)

US covered lives with reimbursement

57 million^R (reported)